The levels of sCD40L and CXCL1 were further compared between controls, minimal-to-mild endometriosis patients (rAFS stage I + II), and moderate-to-severe endometriosis patients (rAFS stage III + IV), which, again, revealed no statistically significant differences between the groups (p = 0.405 and p = 0.921, resp). This evidence concerns the gene CD40LG and endometriosis.